PLAUR and neoplasm: Based on previous evidence, the CTX-based combination with the Src inhibitor-1 or resveratrol (uPAR inhibitor) are shown to overcome CTX resistance in vitro and in vivo (tumor growth suppression and uPAR downstream protein downregulation), respectively.